Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 291 participants.
Also called NCT01508910
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 291 participants
- Sponsor
- Lisata Therapeutics, Inc.
- Registry
-
NCT01508910
-
- Other papers using this trial's data
- The RENEW Trial: Efficacy and Safety of Intramyocardial Autologous CD34(+) Cell Administration in Patients With Refractory Angina
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01508910. Randomized; double masking; primary purpose treatment. Start 2012-04 (registry gives no type); primary completion 2015-11 (actual). Results posted on 2017-02-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina
- Acronym
- RENEW
- Condition
- Chronic Myocardial Ischemia
- Condition
- Refractory Angina Pectoris
- Condition
- Advanced Coronary Heart Disease
- Intervention (Biological)
- Auto-CD34+ cells
- Intervention (Biological)
- Placebo: Diluent used to suspend Auto-CD34+ cells
- Intervention (Other)
- Standard of care
- Lead sponsor
- Lisata Therapeutics, Inc.
Record details
- Record id
cardio:ct-nct01508910- Content hash
a10aaf3f25a947a1eedc3836974e2944154e8d2baaf2a0f86a0c9a93f7933521